6 results
10-K
2019 FY
VIR
Vir Biotechnology Inc
26 Mar 20
Annual report
4:08pm
serious adverse events, or SAEs, have been reported, both in Part B. The first, a Grade 2 headache, resolved with intravenous fluids and non-opioid
424B4
VIR
Vir Biotechnology Inc
11 Oct 19
Prospectus supplement with pricing info
5:31pm
. The first, a Grade 2 headache, resolved with intravenous fluids and non-opioid pain medications. This patient had additional symptoms of fever, nausea
S-1/A
gr5j6i j6064ag
30 Sep 19
IPO registration (amended)
6:12am
- Prev
- 1
- Next